Surgical stapling device including a buttress retention assembly

Information

  • Patent Grant
  • 11672538
  • Patent Number
    11,672,538
  • Date Filed
    Thursday, June 24, 2021
    2 years ago
  • Date Issued
    Tuesday, June 13, 2023
    10 months ago
Abstract
A surgical stapling device includes a tool assembly and a buttress assembly. The tool assembly includes first and second jaw members that are transitionable between closed and open configurations. At least one of the first or second jaw members includes a retention assembly including a support defining a recess. The buttress assembly includes a buttress material and a spine. The buttress material includes first and second portions. The spine includes an elongate portion extending along a length of the first and second portions of the buttress material and an engaging portion attached to the elongate portion in an orthogonal relation. The engaging portion is detachably received in the recess of the support of the retention assembly of the at least one of the first or second jaw members.
Description
TECHNICAL FIELD

The disclosure relates to surgical stapling devices, and more particularly, to assemblies and methods for detachably securing or retaining a staple line buttress assembly to a surgical stapling device.


BACKGROUND

Surgical stapling devices are employed by surgeons to sequentially or simultaneously apply one or more rows of fasteners, e.g., staples or two-part fasteners, to body tissue for the purpose of joining segments of body tissue together. When stapling relatively thin or fragile tissues, it is important to effectively seal the staple line against air or fluid leakage. Additionally, it is often necessary to reinforce the staple line against the tissue to inhibit tears in the tissue or pulling of the staples through the tissue. One method of inhibiting tears or pull through involves the placement of a biocompatible reinforcing material or “buttress” material, between the staples and the underlying tissue. In this method, a layer of buttress assembly is placed against the tissue and the tissue is stapled in the conventional manner.


Accordingly, new systems and methods that enable easy and efficient attachment and removal of a buttress assembly to the surgical stapling device would be desirable.


SUMMARY

The disclosure describes a surgical stapling device including a buttress retention assembly that demonstrates a practical approach to meeting the performance requirements and overcoming usability challenges associated with detachably securing a buttress assembly to a surgical stapling device.


In accordance with the disclosure, a surgical stapling device includes a tool assembly and a buttress assembly. The tool assembly includes first and second jaw members that are transitionable between closed and open configurations. At least one of the first or second jaw members includes a retention assembly including a support defining a recess. The buttress assembly includes a buttress material and a spine. The buttress material includes first and second portions. The spine includes an elongate portion extending along a length of the first and second portions of the buttress material and an engaging portion attached to the elongate portion in an orthogonal relation. The engaging portion is detachably received in the recess of the support of the retention assembly of the at least one of the first or second jaw members.


In an aspect, the buttress material may include a living hinge that connects the first and second portions of the buttress material to each other. The living hinge may bias the first and second portions away from each other.


In another aspect, the first and second portions of the buttress material may define a V-shape profile.


In yet another aspect, the buttress material may be monolithically formed.


In still yet another aspect, the engaging portion of the spine may extend radially outwards from an end portion of the elongate portion of the spine.


In an aspect, the at least one of the first or second jaw members may have a tapered end, and the support of the retention assembly may be disposed on the tapered end.


In another aspect, the support of the retention assembly may have a triangular shape to reduce bending of the buttress material and the spine.


In yet another aspect, the elongate portion of the spine may extend along a peripheral portion of the buttress material.


In still yet another aspect, the engaging portion of the buttress assembly may be releasably secured to the support of the retention assembly by snap fit or friction fit.


In still yet another aspect, the spine of the buttress material may be bioabsorbable.


In still yet another aspect, at least a portion of the elongate portion of the spine may be interposed between the buttress material and the first or second jaw members.


In accordance with another aspect of the disclosure, a surgical kit includes a buttress assembly, a loading assembly, and a surgical stapling device. The buttress assembly includes a buttress material and a first spine. The buttress material includes first and second portions. The first spine includes an elongate portion extending along a length of the first and second portions of the buttress material and engaging portions extending laterally outwards from respective distal end portions of the elongate portion. The loading assembly includes a base portion and an extension extending from the base portion. The base portion includes first and second anchoring assemblies on opposite ends of the base portion. The buttress assembly includes a portion that is wrapped around the extension of the loading assembly. The engaging portions of the first spine of the buttress assembly is detachably secured to the respective first and second anchoring assemblies of the base portion of the loading assembly. The surgical stapling device includes a tool assembly having first and second jaw members that are transitionable between closed and open configurations. The first or second jaw members includes respective retention assemblies. Each retention assembly includes a support defining a recess configured to releasably receive a corresponding engaging portion of the first spine.


In an aspect, the buttress material may further include a living hinge interconnecting the first and second portions of the buttress material. The living hinge may bias the first and second portions away from each other.


In another aspect, the buttress material may be monolithically formed as a single construct.


In yet another aspect, the engaging portions of the first spine may extend from the respective distal end portions of the elongate portion in an orthogonal relation.


In still yet another aspect, the buttress assembly supported on the loading assembly may define a first angle. The first and jaw members may define a second angle in the spaced apart configuration. The first and second angles may be equal.


In still yet another aspect, the buttress assembly may further include a second spine. The first and second spine may be laterally spaced apart and disposed on opposite lateral sides of the buttress material.


In an aspect, the retention assembly of the first or second jaw members may include a pair of supports defining recesses.


In another aspect, the first or second spines may be formed of a bioabsorbable material.


In yet another aspect, the support of the retention assembly of the surgical stapling device may secure the spine thereto by snap fit or interference fit.





BRIEF DESCRIPTION OF DRAWINGS

The above and other aspects and features of this disclosure will become more apparent in view of the following detailed description when taken in conjunction with the accompanying drawings wherein like reference numerals identify similar or identical elements.



FIG. 1 is a perspective view of a surgical stapling device in accordance with the disclosure;



FIG. 2 is a perspective view of a buttress assembly of FIG. 1 for use with the surgical stapling device;



FIG. 3 is an enlarged view of the indicated area of detail of FIG. 1;



FIG. 4 is a partial side view of the surgical stapling device of FIG. 1, illustrating the buttress assembly secured to jaws of a tool assembly of the surgical stapling device;



FIG. 5 is an enlarged view of the indicated area of detail of FIG. 4;



FIG. 6 is a perspective view of a loading assembly for supporting the buttress assembly of FIG. 2 prior to use with the surgical stapling device of FIG. 1;



FIG. 7 is an enlarged view of the indicated area of detail of FIG. 6;



FIGS. 8 and 9 are partial side views of the surgical stapling device of FIG. 1 and the loading assembly of FIG. 6, illustrating transfer of the buttress assembly from the loading assembly to the surgical stapling device; and



FIG. 10 is an enlarged view of the indicated area of detail of FIG. 9.





DETAILED DESCRIPTION

The surgical stapling device including a buttress retention assembly disclosed herein is described in detail with reference to the drawings, in which like reference numerals designate identical or corresponding elements in each of the several views. As used herein, the term “distal” refers to the portion that is being described which is farther from a user in a conventional use of the surgical stapling device, while the term “proximal” refers to the portion that is being described which is closer to a user in a conventional use of the surgical stapling device. In addition, the terms parallel and perpendicular are understood to include relative configurations that are substantially parallel and substantially perpendicular up to about + or −10 degrees from true parallel and true perpendicular. Further, to the extent consistent, any or all of the aspects detailed herein may be used in conjunction with any or all of the other aspects detailed herein.


With reference to FIG. 1, there is provided a surgical stapling device 200 for use in stapling tissue and applying a layer of buttress material between staples and underlying tissue. The layer of buttress material is configured to reinforce and seal staple lines applied to tissue by the surgical stapling device 200. The surgical stapling device 200 generally includes a handle 202 and an elongate tubular member 204 extending distally from the handle 202. A reload 106 is removably coupled to a distal end 105 of the elongate tubular member 204. The reload 106 includes a shaft portion 109 and a tool assembly 107 supported on the shaft portion 109. The tool assembly 107 includes first jaw member 108 and a second jaw member 110 that is movable in relation to the first jaw member 108 between an open configuration for positioning tissue between the first and second jaw members 108, 110 and a closed configuration for clamping tissue between the first and second jaw members 108, 110 and subsequently stapling tissue. The first jaw member 108 supports an anvil 111 and the second jaw member 110 releasably supports a staple cartridge 112. In order to secure the staples provided by the staple cartridge 112 to tissue and a buttress assembly 300, the anvil 111 is provided with longitudinally arranged rows of staple clinching or forming pockets (not shown). It is envisioned that the tool assembly 107 may be coupled to a mechanical or motorized handle, and the staple cartridge 112 may be removable and replaceable. It is also envisioned that the reload 106 may be part of a robotic surgical system.


With continued reference to FIG. 1, the surgical stapling device 200 includes a trigger 236 movably mounted on the handle 202. Actuation of the trigger 236 transitions the tool assembly 107 from the open configuration to the closed configuration and subsequently actuates the surgical stapling device 200 to apply lines of staples to tissue. The surgical stapling device 200 further includes a retraction mechanism 217 that can be manually grasped and pulled proximally to retract a firing mechanism of the surgical stapling device 200. In order to provide proper orientation of the tool assembly 107 relative to tissue to be stapled, the surgical stapling device 200 is additionally provided with a rotation knob 234 mounted on the handle 202. Rotation of the rotation knob 234 about a longitudinal axis “A-A” of the surgical stapling device 200 rotates the tool assembly 107 about the longitudinal axis “A-A.” Reference may be made to U.S. Patent Application Publication No. 2014/0263550, the entire contents of which is incorporated herein by reference, for a detailed discussion of the construction and operation of the surgical stapling device 200.



FIGS. 1 and 2 illustrate a buttress assembly 300 for use with the surgical stapling device 200. The buttress assembly 300 is detachably secured to the tool assembly 107 of the surgical stapling device 200 to be in registration with the anvil 111 of the first jaw member 108 and the staple cartridge 112 of the second jaw member 110. The buttress assembly 300 includes a buttress material 310 and spines 330. The buttress material 310 is configured to reinforce and seal staple lines applied to tissue by the surgical stapling device 200. The buttress material 310 includes first and second portions 312, 316 that define a living hinge 318 therebetween. The living hinge 318 biases the first and second portions 312, 316 away from each other. In an aspect, the buttress material 310 has a V-shape. In an aspect, the buttress material 310 is monolithically formed as a single construct. In another aspect, the buttress material 310 may be formed of an elastic material. The spines 330 are laterally spaced apart and extend along opposing peripheral portions of the buttress material 310. In aspects, the spines 330 are provided to detachably secure the buttress assembly 300 to the first and second jaw members 108, 110 and maintain substantially planar surfaces of the first and second portions 312, 316 of the buttress material 310. Each spine 330 includes an elongate portion 332 that extends along the length of the buttress material 310 and engaging portions 336 that are disposed at opposite ends of the elongate portion 332. Each engaging portion 336 extends laterally outwards from the elongate portion 332 such that the engaging portion 336 is, e.g., orthogonal, to the elongate portion 332. The engaging portion 336 is detachably engageable with the tool assembly 107 (FIG. 1) of the surgical stapling device 200, as will be described. In particular, the elongate portion 332 extends distally from the distal ends 312a, 316a of the first and second portions 312, 316 of the buttress material 310 such that the engaging portions 336 are spaced apart from the distal ends 312a, 316a of the first and second portions 312, 316 of the buttress material 310. In an aspect, each spine 330 is monolithically formed as a single construct. In another aspect, the spines 330 may be formed of a polymer. In another aspect, the spines 330 may be bioabsorbable.


The buttress assembly 300 is detachably securable to the tool assembly 107. To this end, the first and second jaws members 108, 110 include respective first and second retention assemblies 180, 190, as shown in FIGS. 3 and 4. The first retention assembly 180 includes a pair of supports 182. Each support 182 defines a recess 184 to receive a corresponding engaging portion 336 of the spine 330. In an aspect, the engaging portion 336 may be detachably received in the recess 184 via, e.g., snap fit or interference fit. In an aspect, each support 182 of the first retention assembly 180 may include, e.g., a triangular, shape to compensate for the tapering of a distal end portion of the first jaw 108 in order to reduce bending of the spines 330 and/or the buttress material 310, as best shown in FIGS. 4 and 5. FIGS. 3 and 4 further illustrate the second jaw member 110 including the second retention assembly 190. Similar to the first retention assembly 180, the second retention assembly 190 includes a pair of supports 192. Each support 192 defines a recess 194 to receive a corresponding engaging portion 336 of the spine 330. In an aspect, the engaging portion 336 may be detachably received in the recess 194 via, e.g., snap fit or interference fit. In an aspect, each support 192 may include, e.g., a triangular, shape to compensate for the tapering of a distal end portion of the second jaw 110 in order to reduce bending of the spines 330 and/or the buttress material 310, as best shown in FIG. 4.



FIGS. 6 and 7 illustrate a loading assembly 600 releasably supporting the buttress assembly 300 prior to mounting the buttress assembly 300 onto the surgical stapling device 200. The loading assembly 600 facilitates mounting of the buttress assembly 300 on the tool assembly 107 of the surgical stapling device 200. The loading assembly 600 includes a base portion 610 and an extension 650 extending from the base portion 610. In particular, the base portion 610 includes anchoring portions 620, 630 on respective end portions of the base portion 610. The anchoring portions 620, 630 include a respective pair of supports 622, 632 that defines recesses 624 to detachably receive the engaging portions 336 of the spines 330 associated with the first portion 312 of the buttress assembly 300. In an aspect, the engaging portions 336 may be supported in the recesses 624 via, e.g., friction fit. Similarly, the pair of supports 632 of the anchoring portion 630 defines recesses 634 to detachably receive the engaging portions 336 of the spines 330 associated with the second portion 316 the buttress assembly 300. In an aspect, the supports 622 or supports 632 may be spaced apart by a distance “W” that is smaller or greater than a distance “Y” (FIG. 3) defined by the supports 182 or supports 192 of the first or second retention assemblies 180, 190 of the tool assembly 107 such that the first or second retention assemblies 180, 190 may be received within or laterally outwardly of the supports 622 or 632.


Under such a configuration, the buttress assembly 300 is wrapped around the extension 650, and the distal ends 312a, 316a of the buttress material 310 are detachably secured to the respective anchoring portions 620, 630. When the buttress assembly 300 is supported on the loading assembly 600, the first and second portions 312, 316 of the buttress assembly 300 define an angle α (FIG. 6) that is substantially identical to an angle β (FIG. 4) defined by the first and second jaw members 108, 110 in the open configuration.


As shown in FIG. 8, prior to use, the buttress assembly 300 is detachably supported on the loading assembly 600. In use, the loading assembly 600 is positioned between the first and second jaw members 108, 110 with the jaw members 108, 110 in the open configuration. Thereafter, the supports 182, 192 of the first and second retention assemblies 180, 190 of the first and second jaw members 108, 110 are aligned with the supports 622, 632 of the loading assembly 600. The tool assembly 107 and the loading assembly 600 are further moved towards each other until the engaging portions 336 (FIG. 2) of the buttress assembly 300 are received in the recesses 184, 194 (FIGS. 3 and 5) of the first and second retention assemblies 180, 190. In this manner, the buttress assembly 300 is releasably mounted on the tool assembly 107 of the surgical stapling device 200. After the staples have been applied to the tissue, the buttress assembly 300 is attached to tissue and the buttress assembly 300 may be detached from the first and second retention assemblies 180, 190 by pulling the tool assembly 107 away from tissue.


It is further contemplated that the buttress assembly 300 may be made from any biocompatible natural or synthetic material. The material from which the buttress assembly 300 is formed may be bioabsorbable or non-bioabsorbable. It should be understood that any combination of natural, synthetic, bioabsorbable and non-bioabsorbable materials may be used to form the buttress assembly 300.


Some non-limiting examples of materials from which the buttress assembly 300 may be made include but are not limited to poly(lactic acid), poly (glycolic acid), poly (hydroxybutyrate), poly (phosphazine), polyesters, polyethylene glycols, polyethylene oxides, polyacrylamides, polyhydroxyethylmethylacrylate, polyvinylpyrrolidone, polyvinyl alcohols, polyacrylic acid, polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly (ether-esters), polyalkylene oxalates, polyamides, poly (iminocarbonates), polyalkylene oxalates, polyoxaesters, polyorthoesters, polyphosphazenes and copolymers, block copolymers, homopolymers, blends and combinations thereof.


In aspects, natural biological polymers are used in forming the buttress assembly 300. Suitable natural biological polymers include, but are not limited to, collagen, gelatin, fibrin, fibrinogen, elastin, keratin, albumin, hydroxyethyl cellulose, cellulose, hydroxypropyl cellulose, carboxyethyl cellulose, chitan, chitosan, and combinations thereof. In addition, the natural biological polymers may be combined with any of the other polymeric materials described herein to produce the buttress assembly 300.


The buttress assembly 300 may be porous or non-porous, or combinations of porous and non-porous layers. Where the buttress assembly 300 is non-porous, the buttress assembly 300 may retard or inhibit tissue ingrowth from surrounding tissues thereby acting as an adhesion barrier and inhibiting the formation of unwanted scar tissue. Thus, in aspects, the buttress assembly 300 possesses anti-adhesion properties. Techniques for forming non-porous layers from such materials are within the purview of those skilled in the art and include, for example, casting, molding, and the like.


In aspects, the buttress assembly 300 is porous and possesses hemostatic properties. Where the buttress assembly 300 is porous, it has openings or pores over at least a portion of a surface thereof. Suitable materials for forming the porous layer include, but are not limited to foams (e.g., open or closed cell foams). In aspects, the pores may be in sufficient number and size so as to interconnect across the entire thickness of the porous layer. In other aspects, the pores do not interconnect across the entire thickness of the porous layer. In yet other aspects, the pores do not extend across the entire thickness of the porous layer, but rather are present at a portion of the surface thereof. In aspects, the openings or pores are located on a portion of the surface of the porous layer, with other portions of the porous layer having a non-porous texture. Those skilled in the art reading the disclosure will envision other pore distribution patterns and configurations for the porous layer.


Where the buttress assembly 300 is porous, the pores may be formed using any method suitable to forming a foam or sponge including, but not limited to the lyophilization or freeze-drying of a composition. Suitable techniques for making foams are within the purview of those skilled in the art. Porous buttress assembly 300 can be at least 0.2 cm thick, in aspects from about 0.3 to about 1.5 cm thick. Porous buttress assembly 300 can have a density of not more than about 75 mg/cm2 and, in aspects below about 20 mg/cm2. The size of the pores in the porous buttress assembly 300 can be from about 20 μm to about 300 μm, and in certain aspects from about 100 μm to about 200 μm.


The buttress assembly 300 may also include a reinforcement member. The reinforcement member may be associated with a porous or non-porous layer or may be positioned between a non-porous layer and a porous layer of the buttress assembly 300. Alternatively, the reinforcement member may be positioned entirely within one or more of the individual layers (e.g., embedded within the porous layer, the non-porous layer, or both) of the buttress assembly 300. It is also envisioned that the reinforcement member may be positioned at the surface of one of the layers making up the buttress assembly 300 and, in aspects, may be positioned at an exterior surface of the buttress assembly 300.


Some suitable non-limiting examples of reinforcement members include fabrics, meshes, monofilaments, multifilament braids, chopped fibers (sometimes referred to in the art as staple fibers) and combinations thereof. Where the reinforcement member is a mesh, it may be prepared using any technique known to those skilled in the art, such as knitting, weaving, tatting, knipling, or the like. Where monofilaments or multifilament braids are used as the reinforcement member, the monofilaments or multifilament braids may be oriented in any desired manner. For example, the monofilaments or multifilament braids may be randomly positioned with respect to each other within the buttress assembly 300. As another example, the monofilaments or multifilament braids may be oriented in a common direction within the buttress assembly 300. Where chopped fibers are used as the reinforcement member, the chopped fibers may be oriented in any desired manner. For example, the chopped fibers may be randomly oriented or may be oriented in a common direction. The chopped fibers can thus form a non-woven material, such as a mat or a felt. The chopped fibers may be joined together (e.g., by heat fusing) or they may be unattached to each other. The chopped fibers may be of any suitable length. For example, the chopped fibers may be from 0.1 mm to 100 mm in length, and in some aspects, 0.4 mm to 50 mm in length. In an aspect, the buttress assembly 300 has randomly oriented chopped fibers that have not been previously fused together and are embedded within in the buttress assembly 300.


It is envisioned that the reinforcement member may be formed from any bioabsorbable, non-bioabsorbable, natural, or synthetic material previously described herein and combinations thereof. Where monofilaments or multifilament braids are used as the reinforcement member, any commercially available suture material may advantageously be employed as the reinforcement member.


In aspects, at least one bioactive agent may be combined with the buttress assembly 300 and/or any of the individual components (the porous layer, the non-porous layer and/or the reinforcement member) used to construct the buttress assembly 300. In aspects, the buttress assembly 300 can also serve as a vehicle for delivery of the bioactive agent. The term “bioactive agent”, as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye, or fragrance. Alternatively, a bioactive agent could be any agent which provides a therapeutic or prophylactic effect such as a compound that affects or participates in tissue growth, cell growth, or cell differentiation.


Examples of classes of bioactive agents which may be utilized in accordance with the disclosure include anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, and enzymes. It is also intended that combinations of bioactive agents may be used.


Anti-adhesive or anti-adhesion agents can be used to inhibit adhesions from forming between the buttress assembly 300 and the surrounding tissues opposite the target tissue. Some examples of these agents include, but are not limited to poly (vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, polyethylene oxide, poly vinyl alcohols and combinations thereof.


Suitable antimicrobial agents which may be included as a bioactive agent in the buttress assembly 300 of the disclosure include triclosan, also known as 2,4,4′-trichloro-2′-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and pipracil, nonoxynol 9, fusidic acid, cephalosporins, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a bioactive agent in the bioactive coating of the disclosure.


Other bioactive agents which may be included as a bioactive agent in the buttress assembly 300 in accordance with the disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; estrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents.


Other examples of suitable bioactive agents which may be included in the coating composition include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g. lymphokines, monokines, chemokines), blood clotting factors, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons (β-IFN, (α-IFN and γ-IFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MC SF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA and RNA; oligonucleotides; polynucleotides; and ribozymes.


While the disclosure has been shown in the drawings, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.

Claims
  • 1. A surgical stapling device comprising: a tool assembly including first and second jaw members that are transitionable between closed and open configurations, at least one of the first or second jaw members including a retention assembly including a support defining a recess; anda buttress assembly including: a buttress material including first and second portions; anda spine including an elongate portion extending along a length of the first and second portions of the buttress material and an engaging portion attached to the elongate portion in an orthogonal relation, the engaging portion detachably received in the recess of the support of the retention assembly of the at least one of the first or second jaw members.
  • 2. The surgical stapling device according to claim 1, wherein the buttress material includes a living hinge that connects the first and second portions of the buttress material to each other, the living hinge biasing the first and second portions away from each other.
  • 3. The surgical stapling device according to claim 1, wherein the first and second portions of the buttress material defines a V-shape profile.
  • 4. The surgical stapling device according to claim 1, wherein the buttress material is monolithically formed.
  • 5. The surgical stapling device according to claim 1, wherein the engaging portion of the spine extends radially outwards from an end portion of the elongate portion of the spine.
  • 6. The surgical stapling device according to claim 1, wherein the at least one of the first or second jaw members has a tapered end, and the support of the retention assembly is disposed on the tapered end.
  • 7. The surgical stapling device according to claim 6, wherein the support of the retention assembly has a triangular shape to reduce bending of the buttress material and the spine.
  • 8. The surgical stapling device according to claim 1, wherein the elongate portion of the spine extends along a peripheral portion of the buttress material.
  • 9. The surgical stapling device according to claim 1, wherein the engaging portion of the buttress assembly is releasably secured to the support of the retention assembly by snap fit or friction fit.
  • 10. The surgical stapling device according to claim 1, wherein the spine of the buttress material is bioabsorbable.
  • 11. The surgical stapling device according to claim 1, wherein at least a portion of the elongate portion of the spine is interposed between the buttress material and the first or second jaw members.
  • 12. A surgical kit comprising: a buttress assembly including: a buttress material including first and second portions; anda first spine including an elongate portion extending along a length of the first and second portions of the buttress material and engaging portions extending laterally outwards from respective distal end portions of the elongate portion;a loading assembly including a base portion and an extension extending from the base portion, the base portion including first and second anchoring assemblies on opposite ends of the base portion, the buttress assembly including a portion that is wrapped around the extension of the loading assembly, the engaging portions of the first spine of the buttress assembly being detachably secured to the respective first and second anchoring assemblies of the base portion of the loading assembly; anda surgical stapling device including a tool assembly having first and second jaw members that are transitionable between closed and open configurations, the first or second jaw members including respective retention assemblies, each retention assembly including a support defining a recess configured to releasably receive a corresponding engaging portion of the first spine.
  • 13. The surgical kit according to claim 12, wherein the buttress material further includes a living hinge interconnecting the first and second portions of the buttress material, the living hinge biasing the first and second portions away from each other.
  • 14. The surgical kit according to claim 12, wherein the buttress material is monolithically formed as a single construct.
  • 15. The surgical kit according to claim 12, wherein the engaging portions of the first spine extend from the respective distal end portions of the elongate portion in an orthogonal relation.
  • 16. The surgical kit according to claim 12, wherein the buttress assembly supported on the loading assembly defines a first angle, the first and jaw members define a second angle in the spaced apart configuration, the first and second angles being equal.
  • 17. The surgical kit according to claim 12, wherein the buttress assembly further includes a second spine, the first and second spine being laterally spaced apart and disposed on opposite lateral sides of the buttress material.
  • 18. The surgical kit according to claim 17, wherein the retention assembly of the first or second jaw members includes a pair of supports defining recesses.
  • 19. The surgical kit according to claim 17, wherein the first or second spines is formed of a bioabsorbable material.
  • 20. The surgical kit according to claim 12, wherein the support of the retention assembly of the surgical stapling device secures the spine thereto by snap fit or interference fit.
US Referenced Citations (546)
Number Name Date Kind
3054406 Usher Sep 1962 A
3124136 Usher Mar 1964 A
3364200 Ashton et al. Jan 1968 A
3499591 Green Mar 1970 A
3797494 Zaffaroni Mar 1974 A
3939068 Wendt et al. Feb 1976 A
3948666 Kitanishi et al. Apr 1976 A
4064062 Yurko Dec 1977 A
4166800 Fong Sep 1979 A
4282236 Broom Aug 1981 A
4347847 Usher Sep 1982 A
4354628 Green Oct 1982 A
4416698 McCorsley, III Nov 1983 A
4429695 Green Feb 1984 A
4452245 Usher Jun 1984 A
4605730 Shalaby et al. Aug 1986 A
4626253 Broadnax, Jr. Dec 1986 A
4655221 Devereux Apr 1987 A
4834090 Moore May 1989 A
4838884 Dumican et al. Jun 1989 A
4927640 Dahlinder et al. May 1990 A
4930674 Barak Jun 1990 A
5002551 Linsky et al. Mar 1991 A
5014899 Presty et al. May 1991 A
5040715 Green et al. Aug 1991 A
5057334 Vail Oct 1991 A
5065929 Schulze et al. Nov 1991 A
5112496 Dhawan et al. May 1992 A
5162430 Rhee et al. Nov 1992 A
5205459 Brinkerhoff et al. Apr 1993 A
5263629 Trumbull et al. Nov 1993 A
5281197 Arias et al. Jan 1994 A
5307976 Olson et al. May 1994 A
5312023 Green et al. May 1994 A
5314471 Brauker et al. May 1994 A
5318221 Green et al. Jun 1994 A
5324775 Rhee et al. Jun 1994 A
5326013 Green et al. Jul 1994 A
5332142 Robinson et al. Jul 1994 A
5344454 Clarke et al. Sep 1994 A
5392979 Green et al. Feb 1995 A
5397324 Carroll et al. Mar 1995 A
5405072 Zlock et al. Apr 1995 A
5410016 Hubbell et al. Apr 1995 A
5425745 Green et al. Jun 1995 A
5441193 Gravener Aug 1995 A
5441507 Wilk Aug 1995 A
5443198 Viola et al. Aug 1995 A
5468253 Bezwada et al. Nov 1995 A
5484913 Stilwell et al. Jan 1996 A
5503638 Cooper et al. Apr 1996 A
5514379 Weissleder et al. May 1996 A
5542594 McKean et al. Aug 1996 A
5543441 Rhee et al. Aug 1996 A
5549628 Cooper et al. Aug 1996 A
5550187 Rhee et al. Aug 1996 A
5575803 Cooper et al. Nov 1996 A
5645915 Kranzler et al. Jul 1997 A
5653756 Clarke et al. Aug 1997 A
5683809 Freeman et al. Nov 1997 A
5690675 Sawyer et al. Nov 1997 A
5702409 Raybum et al. Dec 1997 A
5752965 Francis et al. May 1998 A
5752974 Rhee et al. May 1998 A
5762256 Mastri et al. Jun 1998 A
5766188 Igaki Jun 1998 A
5769892 Kingwell Jun 1998 A
5782396 Mastri et al. Jul 1998 A
5799857 Robertson et al. Sep 1998 A
5810855 Rayburn et al. Sep 1998 A
5814057 Oi et al. Sep 1998 A
5819350 Wang Oct 1998 A
5833695 Yoon Nov 1998 A
5843096 Igaki et al. Dec 1998 A
5871135 Williamson, IV et al. Feb 1999 A
5874500 Rhee et al. Feb 1999 A
5895412 Tucker Apr 1999 A
5895415 Chow et al. Apr 1999 A
5902312 Frater et al. May 1999 A
5908427 McKean et al. Jun 1999 A
5915616 Viola et al. Jun 1999 A
5931847 Bittner et al. Aug 1999 A
5957363 Heck Sep 1999 A
5964774 McKean et al. Oct 1999 A
5997895 Narotam et al. Dec 1999 A
6019791 Wood Feb 2000 A
6030392 Dakov Feb 2000 A
6032849 Mastri et al. Mar 2000 A
6045560 McKean et al. Apr 2000 A
6063097 Oi et al. May 2000 A
6080169 Turtel Jun 2000 A
6093557 Pui et al. Jul 2000 A
6099551 Gabbay Aug 2000 A
6142933 Longo et al. Nov 2000 A
6149667 Hovland et al. Nov 2000 A
6152943 Sawhney Nov 2000 A
6155265 Hammerslag Dec 2000 A
6156677 Brown Reed et al. Dec 2000 A
6165201 Sawhney et al. Dec 2000 A
6179862 Sawhney Jan 2001 B1
6210439 Firmin et al. Apr 2001 B1
6214020 Mulhauser et al. Apr 2001 B1
6241139 Milliman et al. Jun 2001 B1
6258107 Balazs et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6270530 Eldridge et al. Aug 2001 B1
6273897 Dalessandro et al. Aug 2001 B1
6280453 Kugel et al. Aug 2001 B1
6299631 Shalaby Oct 2001 B1
6309569 Farrar et al. Oct 2001 B1
6312457 DiMatteo et al. Nov 2001 B1
6312474 Francis et al. Nov 2001 B1
6325810 Hamilton et al. Dec 2001 B1
6330965 Milliman et al. Dec 2001 B1
6399362 Pui et al. Jun 2002 B1
6436030 Rehil Aug 2002 B2
6454780 Wallace Sep 2002 B1
6461368 Fogarty et al. Oct 2002 B2
6500777 Wiseman et al. Dec 2002 B1
6503257 Grant et al. Jan 2003 B2
6514283 DiMatteo et al. Feb 2003 B2
6514534 Sawhney Feb 2003 B1
6517566 Hovland et al. Feb 2003 B1
6551356 Rousseau Apr 2003 B2
6566406 Pathak et al. May 2003 B1
6568398 Cohen May 2003 B2
6590095 Schleicher et al. Jul 2003 B1
6592597 Grant et al. Jul 2003 B2
6605294 Sawhney Aug 2003 B2
6610006 Amid et al. Aug 2003 B1
6627749 Kumar Sep 2003 B1
6638285 Gabbay Oct 2003 B2
6652594 Francis et al. Nov 2003 B2
6656193 Grant et al. Dec 2003 B2
6656200 Li et al. Dec 2003 B2
6669735 Pelissier Dec 2003 B1
6673093 Sawhney Jan 2004 B1
6677258 Carroll et al. Jan 2004 B2
6685714 Rousseau Feb 2004 B2
6702828 Whayne Mar 2004 B2
6703047 Sawhney et al. Mar 2004 B2
6704210 Myers Mar 2004 B1
6723114 Shalaby Apr 2004 B2
6726706 Dominguez Apr 2004 B2
6736823 Darois et al. May 2004 B2
6736854 Vadurro et al. May 2004 B2
6746458 Cloud Jun 2004 B1
6746869 Pui et al. Jun 2004 B2
6764720 Pui et al. Jul 2004 B2
6773458 Brauker et al. Aug 2004 B1
6818018 Sawhney Nov 2004 B1
6843252 Harrison et al. Jan 2005 B2
6896684 Monassevitch et al. May 2005 B2
6927315 Heinecke et al. Aug 2005 B1
6939358 Palacios et al. Sep 2005 B2
6946196 Foss Sep 2005 B2
6953139 Milliman et al. Oct 2005 B2
6959851 Heinrich Nov 2005 B2
7009034 Pathak et al. Mar 2006 B2
7025772 Gellman et al. Apr 2006 B2
7060087 DiMatteo et al. Jun 2006 B2
7087065 Ulmsten et al. Aug 2006 B2
7108701 Evens et al. Sep 2006 B2
7128253 Mastri et al. Oct 2006 B2
7128748 Mooradian et al. Oct 2006 B2
7134438 Makower et al. Nov 2006 B2
7141055 Abrams et al. Nov 2006 B2
7147138 Shelton, IV Dec 2006 B2
7160299 Baily Jan 2007 B2
7179268 Roy et al. Feb 2007 B2
7210810 Iversen et al. May 2007 B1
7214727 Kwon et al. May 2007 B2
7232449 Sharkawy et al. Jun 2007 B2
7241300 Sharkawy et al. Jul 2007 B2
7247338 Pui et al. Jul 2007 B2
7279322 Pui et al. Oct 2007 B2
7307031 Carroll et al. Dec 2007 B2
7308998 Mastri et al. Dec 2007 B2
7311720 Mueller et al. Dec 2007 B2
7328829 Arad et al. Feb 2008 B2
7334717 Rethy et al. Feb 2008 B2
7347850 Sawhney Mar 2008 B2
7377928 Zubik et al. May 2008 B2
7434717 Shelton, IV et al. Oct 2008 B2
7438209 Hess et al. Oct 2008 B1
7464849 Shelton, IV et al. Dec 2008 B2
7498063 Pui et al. Mar 2009 B2
7547312 Bauman et al. Jun 2009 B2
7559937 de la Torre et al. Jul 2009 B2
7571845 Viola Aug 2009 B2
7592418 Pathak et al. Sep 2009 B2
7594921 Browning Sep 2009 B2
7595392 Kumar et al. Sep 2009 B2
7604151 Hess et al. Oct 2009 B2
7611494 Campbell et al. Nov 2009 B2
7635073 Heinrich Dec 2009 B2
7645874 Saferstein et al. Jan 2010 B2
7649089 Kumar et al. Jan 2010 B2
7655288 Bauman et al. Feb 2010 B2
7662409 Masters Feb 2010 B2
7662801 Kumar et al. Feb 2010 B2
7665646 Prommersberger Feb 2010 B2
7666198 Suyker et al. Feb 2010 B2
7669747 Weisenburgh, II et al. Mar 2010 B2
7673782 Hess et al. Mar 2010 B2
7708180 Murray et al. May 2010 B2
7709631 Harris et al. May 2010 B2
7717313 Criscuolo et al. May 2010 B2
7722642 Williamson, IV et al. May 2010 B2
7735703 Morgan et al. Jun 2010 B2
7744627 Orban, III et al. Jun 2010 B2
7754002 Maase et al. Jul 2010 B2
7776060 Mooradian et al. Aug 2010 B2
7789889 Zubik et al. Sep 2010 B2
7793813 Bettuchi Sep 2010 B2
7799026 Schechter et al. Sep 2010 B2
7819896 Racenet Oct 2010 B2
7823592 Bettuchi et al. Nov 2010 B2
7824420 Eldridge et al. Nov 2010 B2
7845533 Marczyk et al. Dec 2010 B2
7845536 Viola et al. Dec 2010 B2
7846149 Jankowski Dec 2010 B2
7892247 Conston et al. Feb 2011 B2
7909224 Prommersberger Mar 2011 B2
7909837 Crews et al. Mar 2011 B2
7938307 Bettuchi May 2011 B2
7942890 D'Agostino et al. May 2011 B2
7950561 Aranyi May 2011 B2
7951166 Orban, III et al. May 2011 B2
7951248 Fallis et al. May 2011 B1
7967179 Olson et al. Jun 2011 B2
7988027 Olson et al. Aug 2011 B2
8011550 Aranyi et al. Sep 2011 B2
8011555 Tarinelli et al. Sep 2011 B2
8016177 Bettuchi et al. Sep 2011 B2
8016178 Olson et al. Sep 2011 B2
8025199 Whitman et al. Sep 2011 B2
8028883 Stopek Oct 2011 B2
8033483 Fortier et al. Oct 2011 B2
8033983 Chu et al. Oct 2011 B2
8038045 Bettuchi et al. Oct 2011 B2
8062330 Prommersberger et al. Nov 2011 B2
8062673 Figuly et al. Nov 2011 B2
8083119 Prommersberger Dec 2011 B2
8091756 Viola Jan 2012 B2
8123766 Bauman et al. Feb 2012 B2
8123767 Bauman et al. Feb 2012 B2
8127975 Olson et al. Mar 2012 B2
8133336 Kettlewell et al. Mar 2012 B2
8133559 Lee et al. Mar 2012 B2
8146791 Bettuchi et al. Apr 2012 B2
8152777 Campbell et al. Apr 2012 B2
8157149 Olson et al. Apr 2012 B2
8157151 Ingmanson et al. Apr 2012 B2
8167895 D'Agostino et al. May 2012 B2
8177797 Shimoji et al. May 2012 B2
8178746 Hildeberg et al. May 2012 B2
8192460 Orban, III et al. Jun 2012 B2
8201720 Hessler Jun 2012 B2
8210414 Bettuchi et al. Jul 2012 B2
8210453 Hull et al. Jul 2012 B2
8225799 Bettuchi Jul 2012 B2
8225981 Criscuolo et al. Jul 2012 B2
8231043 Tarinelli et al. Jul 2012 B2
8235273 Olson et al. Aug 2012 B2
8245901 Stopek Aug 2012 B2
8252339 Figuly et al. Aug 2012 B2
8252921 Vignon et al. Aug 2012 B2
8256654 Bettuchi et al. Sep 2012 B2
8257391 Orban, III et al. Sep 2012 B2
8276800 Bettuchi Oct 2012 B2
8286849 Bettuchi Oct 2012 B2
8308042 Aranyi Nov 2012 B2
8308045 Bettuchi et al. Nov 2012 B2
8308046 Prommersberger Nov 2012 B2
8312885 Bettuchi et al. Nov 2012 B2
8313014 Bettuchi Nov 2012 B2
8317790 Bell et al. Nov 2012 B2
8322590 Patel et al. Dec 2012 B2
8348126 Olson et al. Jan 2013 B2
8348130 Shah et al. Jan 2013 B2
8365972 Aranyi et al. Feb 2013 B2
8367089 Wan et al. Feb 2013 B2
8371491 Huitema et al. Feb 2013 B2
8371492 Aranyi et al. Feb 2013 B2
8371493 Aranyi et al. Feb 2013 B2
8372094 Bettuchi et al. Feb 2013 B2
8393514 Shelton, IV et al. Mar 2013 B2
8393517 Milo Mar 2013 B2
8408440 Olson et al. Apr 2013 B2
8408480 Hull et al. Apr 2013 B2
8413869 Heinrich Apr 2013 B2
8413871 Racenet et al. Apr 2013 B2
8418909 Kostrzewski Apr 2013 B2
8424742 Bettuchi Apr 2013 B2
8453652 Stopek Jun 2013 B2
8453904 Eskaros et al. Jun 2013 B2
8453909 Olson et al. Jun 2013 B2
8453910 Bettuchi et al. Jun 2013 B2
8464925 Hull et al. Jun 2013 B2
8470360 McKay Jun 2013 B2
8474677 Woodard, Jr. et al. Jul 2013 B2
8479968 Hodgkinson et al. Jul 2013 B2
8485414 Criscuolo et al. Jul 2013 B2
8496683 Prommersberger et al. Jul 2013 B2
8511533 Viola et al. Aug 2013 B2
8512402 Marczyk et al. Aug 2013 B2
8518440 Blaskovich et al. Aug 2013 B2
8529600 Woodard, Jr. et al. Sep 2013 B2
8540128 Shelton, IV et al. Sep 2013 B2
8540131 Swayze Sep 2013 B2
8551138 Orban, III et al. Oct 2013 B2
8556918 Bauman et al. Oct 2013 B2
8561873 Ingmanson et al. Oct 2013 B2
8579990 Priewe Nov 2013 B2
8584920 Hodgkinson Nov 2013 B2
8590762 Hess et al. Nov 2013 B2
8616430 (Prommersberger) Stopek et al. Dec 2013 B2
8617132 Golzarian et al. Dec 2013 B2
8631989 Aranyi et al. Jan 2014 B2
8646674 Schulte et al. Feb 2014 B2
8668129 Olson Mar 2014 B2
8678263 Viola Mar 2014 B2
8679137 Bauman et al. Mar 2014 B2
8684250 Bettuchi et al. Apr 2014 B2
8701958 Shelton, IV et al. Apr 2014 B2
8721703 Fowler May 2014 B2
8727197 Hess et al. May 2014 B2
8757466 Olson et al. Jun 2014 B2
8789737 Hodgkinson et al. Jul 2014 B2
8814888 Sgro Aug 2014 B2
8820606 Hodgkinson Sep 2014 B2
8827133 Shelton, IV et al. Sep 2014 B2
8857694 Shelton, IV et al. Oct 2014 B2
8864009 Shelton, IV et al. Oct 2014 B2
8870050 Hodgkinson Oct 2014 B2
8920443 Hiles et al. Dec 2014 B2
8920444 Hiles et al. Dec 2014 B2
8939344 Olson et al. Jan 2015 B2
8956390 Shah et al. Feb 2015 B2
8967448 Carter et al. Mar 2015 B2
9005243 Stopek et al. Apr 2015 B2
9010606 Aranyi et al. Apr 2015 B2
9010608 Casasanta, Jr. et al. Apr 2015 B2
9010609 Carter et al. Apr 2015 B2
9010610 Hodgkinson Apr 2015 B2
9010612 Stevenson et al. Apr 2015 B2
9016543 (Prommersberger) Stopek et al. Apr 2015 B2
9016544 Hodgkinson et al. Apr 2015 B2
9027817 Milliman et al. May 2015 B2
9044227 Shelton, IV et al. Jun 2015 B2
9055944 Hodgkinson et al. Jun 2015 B2
9084602 Gleiman Jul 2015 B2
9107665 Hodgkinson et al. Aug 2015 B2
9107667 Hodgkinson Aug 2015 B2
9113871 Milliman et al. Aug 2015 B2
9113873 Marczyk et al. Aug 2015 B2
9113885 Hodgkinson et al. Aug 2015 B2
9113893 Sorrentino et al. Aug 2015 B2
9161753 Prior Oct 2015 B2
9161757 Bettuchi Oct 2015 B2
9186140 Hiles et al. Nov 2015 B2
9186144 Stevenson et al. Nov 2015 B2
9192378 Aranyi et al. Nov 2015 B2
9192379 Aranyi et al. Nov 2015 B2
9192380 (Tarinelli) Racenet et al. Nov 2015 B2
9192383 Milliman Nov 2015 B2
9192384 Bettuchi Nov 2015 B2
9198660 Hodgkinson Dec 2015 B2
9198663 Marczyk et al. Dec 2015 B1
9204881 Penna Dec 2015 B2
9220504 Viola et al. Dec 2015 B2
9226754 D'Agostino et al. Jan 2016 B2
9237892 Hodgkinson Jan 2016 B2
9237893 Carter et al. Jan 2016 B2
9277922 Carter et al. Mar 2016 B2
9295466 Hodgkinson et al. Mar 2016 B2
9326768 Shelton, IV May 2016 B2
9326773 Casasanta, Jr. et al. May 2016 B2
9328111 Zhou et al. May 2016 B2
9345479 (Tarinelli) Racenet et al. May 2016 B2
9351729 Orban, III et al. May 2016 B2
9351731 Carter et al. May 2016 B2
9351732 Hodgkinson May 2016 B2
9358005 Shelton, IV et al. Jun 2016 B2
9364229 D'Agostino et al. Jun 2016 B2
9364234 (Prommersberger) Stopek et al. Jun 2016 B2
9386988 Baxter, III et al. Jul 2016 B2
9402627 Stevenson et al. Aug 2016 B2
9414839 Penna Aug 2016 B2
9433412 Bettuchi et al. Sep 2016 B2
9433413 Stopek Sep 2016 B2
9433420 Hodgkinson Sep 2016 B2
9445812 Olson et al. Sep 2016 B2
9445817 Bettuchi Sep 2016 B2
9463260 Stopek Oct 2016 B2
9486215 Olson et al. Nov 2016 B2
9492170 Bear et al. Nov 2016 B2
9504470 Milliman Nov 2016 B2
9517164 Vitaris et al. Dec 2016 B2
9572576 Hodgkinson et al. Feb 2017 B2
9585657 Shelton, IV et al. Mar 2017 B2
9597077 Hodgkinson Mar 2017 B2
9610080 Whitfield et al. Apr 2017 B2
9622745 Ingmanson et al. Apr 2017 B2
9629626 Soltz et al. Apr 2017 B2
9636850 Stopek (nee Prommersberger) et al. May 2017 B2
9655620 Prescott et al. May 2017 B2
9675351 Hodgkinson et al. Jun 2017 B2
9681936 Hodgkinson et al. Jun 2017 B2
9687262 Rousseau et al. Jun 2017 B2
9693772 Ingmanson et al. Jul 2017 B2
9708184 Chan et al. Jul 2017 B2
9770245 Swayze et al. Sep 2017 B2
9775617 Carter et al. Oct 2017 B2
9775618 Bettuchi et al. Oct 2017 B2
9782173 Mozdzierz Oct 2017 B2
9844378 Casasanta et al. Dec 2017 B2
9918713 Zergiebel et al. Mar 2018 B2
9931116 Racenet et al. Apr 2018 B2
10022125 (Prommersberger) Stopek et al. Jul 2018 B2
10098639 Hodgkinson Oct 2018 B2
10111659 Racenet et al. Oct 2018 B2
10154840 Viola et al. Dec 2018 B2
20020091397 Chen Jul 2002 A1
20020151911 Gabbay Oct 2002 A1
20030065345 Weadock Apr 2003 A1
20030078209 Schmidt Apr 2003 A1
20030083676 Wallace May 2003 A1
20030125676 Swenson et al. Jul 2003 A1
20030181927 Wallace Sep 2003 A1
20030208231 Williamson et al. Nov 2003 A1
20040092912 Jinno et al. May 2004 A1
20040107006 Francis et al. Jun 2004 A1
20040131418 Budde et al. Jul 2004 A1
20040254590 Hoffman et al. Dec 2004 A1
20040260315 Dell et al. Dec 2004 A1
20050002981 Lahtinen et al. Jan 2005 A1
20050006429 Wales et al. Jan 2005 A1
20050021085 Abrams et al. Jan 2005 A1
20050059996 Bauman et al. Mar 2005 A1
20050059997 Bauman et al. Mar 2005 A1
20050070929 Dalessandro et al. Mar 2005 A1
20050118435 DeLucia et al. Jun 2005 A1
20050149073 Arani et al. Jul 2005 A1
20050283256 Sommerich et al. Dec 2005 A1
20060008505 Brandon Jan 2006 A1
20060121266 Fandel et al. Jun 2006 A1
20060173470 Oray et al. Aug 2006 A1
20060190027 Downey Aug 2006 A1
20070034669 de la Torre Feb 2007 A1
20070203510 Bettuchi Aug 2007 A1
20070243227 Gertner Oct 2007 A1
20070246505 Pace-Floridia et al. Oct 2007 A1
20080009811 Cantor Jan 2008 A1
20080029570 Shelton et al. Feb 2008 A1
20080082126 Murray et al. Apr 2008 A1
20080140115 Stopek Jun 2008 A1
20080169328 Shelton Jul 2008 A1
20080169332 Shelton et al. Jul 2008 A1
20080169333 Shelton et al. Jul 2008 A1
20080216855 Nasca Sep 2008 A1
20080220047 Sawhney et al. Sep 2008 A1
20080290134 Bettuchi et al. Nov 2008 A1
20090001121 Hess et al. Jan 2009 A1
20090001130 Hess et al. Jan 2009 A1
20090031842 Kawai et al. Feb 2009 A1
20090206125 Huitema et al. Aug 2009 A1
20090206126 Huitema et al. Aug 2009 A1
20090206139 Hall et al. Aug 2009 A1
20090206141 Huitema et al. Aug 2009 A1
20090206142 Huitema et al. Aug 2009 A1
20090218384 Aranyi Sep 2009 A1
20090277944 Dalessandro et al. Nov 2009 A9
20100016855 Ramstein et al. Jan 2010 A1
20100016888 Calabrese et al. Jan 2010 A1
20100087840 Ebersole et al. Apr 2010 A1
20100147921 Olson Jun 2010 A1
20100147922 Olson Jun 2010 A1
20100174253 Cline et al. Jul 2010 A1
20100203151 Hiraoka Aug 2010 A1
20100243707 Olson et al. Sep 2010 A1
20100331859 Omori Dec 2010 A1
20110034910 Ross et al. Feb 2011 A1
20110089220 Ingmanson et al. Apr 2011 A1
20110125138 Malinouskas et al. May 2011 A1
20110166673 Patel et al. Jul 2011 A1
20110293690 Griffin et al. Dec 2011 A1
20120080336 Shelton, IV et al. Apr 2012 A1
20120197272 Oray et al. Aug 2012 A1
20120241491 Aldridge et al. Sep 2012 A1
20120241493 Baxter, III et al. Sep 2012 A1
20120253298 Henderson et al. Oct 2012 A1
20130153636 Shelton, IV et al. Jun 2013 A1
20130153641 Shelton, IV et al. Jun 2013 A1
20130256380 Schmid et al. Oct 2013 A1
20140048580 Merchant et al. Feb 2014 A1
20140131418 Kostrzewski May 2014 A1
20140224686 Aronhalt et al. Aug 2014 A1
20140239047 Hodgkinson et al. Aug 2014 A1
20140263550 Aranyi et al. Sep 2014 A1
20150041347 Hodgkinson Feb 2015 A1
20150133995 Shelton, IV et al. May 2015 A1
20150157321 Zergiebel et al. Jun 2015 A1
20150209045 Hodgkinson et al. Jul 2015 A1
20150231409 Racenet et al. Aug 2015 A1
20150327864 Hodgkinson et al. Nov 2015 A1
20160022268 Prior Jan 2016 A1
20160045200 Milliman Feb 2016 A1
20160100834 Viola et al. Apr 2016 A1
20160106430 Carter et al. Apr 2016 A1
20160128694 Baxter, III et al. May 2016 A1
20160157857 Hodgkinson et al. Jun 2016 A1
20160174988 D'Agostino et al. Jun 2016 A1
20160206315 Olson Jul 2016 A1
20160220257 Casasanta et al. Aug 2016 A1
20160249923 Hodgkinson et al. Sep 2016 A1
20160270793 Carter et al. Sep 2016 A1
20160310143 Bettuchi Oct 2016 A1
20160338704 Penna Nov 2016 A1
20160367252 Olson et al. Dec 2016 A1
20160367253 Hodgkinson Dec 2016 A1
20160367257 Stevenson et al. Dec 2016 A1
20170042540 Olson et al. Feb 2017 A1
20170049452 Milliman Feb 2017 A1
20170119390 Schellin et al. May 2017 A1
20170150967 Hodgkinson et al. Jun 2017 A1
20170172575 Hodgkinson Jun 2017 A1
20170231629 Stopek et al. Aug 2017 A1
20170238931 Prescott et al. Aug 2017 A1
20170281328 Hodgkinson, Ph.D et al. Oct 2017 A1
20170296188 Ingmanson et al. Oct 2017 A1
20170354415 Casasanta, Jr. et al. Dec 2017 A1
20180125491 Aranyi May 2018 A1
20180140301 Milliman May 2018 A1
20180168654 Hodgkinson et al. Jun 2018 A1
20180214147 Merchant et al. Aug 2018 A1
20180229054 Racenet et al. Aug 2018 A1
20180250000 Hodgkinson et al. Sep 2018 A1
20180256164 Aranyi Sep 2018 A1
20180296214 Hodgkinson et al. Oct 2018 A1
20180310937 (Prommersberger) Stopek et al. Nov 2018 A1
20190021734 Hodgkinson Jan 2019 A1
20190059878 (Tarinelli) Racenet et al. Feb 2019 A1
20190083087 Viola et al. Mar 2019 A1
20210177415 Shelton, IV et al. Jun 2021 A1
Foreign Referenced Citations (19)
Number Date Country
2282761 Sep 1998 CA
1602563 Mar 1950 DE
19924311 Nov 2000 DE
0327022 Aug 1989 EP
0594148 Apr 1994 EP
2462880 Jun 2012 EP
2491867 Aug 2012 EP
3150142 Apr 2017 EP
2000166933 Jun 2000 JP
2002202213 Jul 2002 JP
2007124166 May 2007 JP
2010214132 Sep 2010 JP
9005489 May 1990 WO
9516221 Jun 1995 WO
9838923 Sep 1998 WO
9926826 Jun 1999 WO
0010456 Mar 2000 WO
0016684 Mar 2000 WO
2010075298 Jul 2010 WO
Non-Patent Literature Citations (174)
Entry
Extended European Search Report corresponding to EP 14 16 9739.1, completed Aug. 19, 2014 and dated Aug. 29, 2014; (7 pp).
Extended European Search Report corresponding to EP 14 15 7997.9, completed Sep. 9, 2014 and dated Sep. 17, 2014; (8 pp).
Extended European Search Report corresponding to EP 14 16 8904.2, completed Sep. 10, 2014 and dated Sep. 18, 2014; (8 pp).
Extended European Search Report corresponding to EP 13 19 4995.0, completed Jun. 5, 2014 and dated Oct. 13, 2014; (10 pp).
Extended European Search Report corresponding to EP 13 15 4571.7, completed Oct. 10, 2014 and dated Oct. 20, 2014; (8 pp).
Extended European Search Report corresponding to EP 14 18 1125.7, completed Oct. 16, 2014 and dated Oct. 24, 2014; (7 pp).
Extended European Search Report corresponding to EP 14 18 1127.3, completed Oct. 16, 2014 and dated Nov. 10, 2014; (8 pp).
Extended European Search Report corresponding to EP 14 19 0419.3, completed Mar. 24, 2015 and dated Mar. 30, 2015; (6 pp).
European Office Action corresponding to EP 12 198 776.2 dated Apr. 7, 2015.
European Office Action corresponding to EP 13 156 297.7 dated Apr. 10, 2015.
Australian Examination Report No. 1 corresponding to AU 2011250822 dated May 18, 2015.
European Office Action corresponding to EP 12 186 175.1 dated Jun. 1, 2015.
Chinese Office Action corresponding to CN 201010517292.8 dated Jun. 2, 2015.
Extended European Search Report corresponding to EP 14 17 4814.5 dated Jun. 9, 2015.
Australian Examination Report No. 1 corresponding to AU 2014200584 dated Jun. 15, 2015.
European Office Action corresponding to EP 13 180 881.8 dated Jun. 19, 2015.
European Office Action corresponding to EP 14 157 195.0 dated Jul. 2, 2015.
Extended European Search Report corresponding to EP 12 19 6902.6 dated Aug. 6, 2015.
Extended European Search Report corresponding to EP 14 15 2060.1 dated Aug. 14, 2015.
Chinese Office Action corresponding to CN 201210129787.2 dated Aug. 24, 2015.
Canadian Office Action corresponding to CA 2,665,206 dated Nov. 19, 2013.
Chinese Notification of Reexamination corresponding to CN 201010517292.8 dated Jun. 2, 2015.
Japanese Office Action corresponding to JP 2014-216989 dated Sep. 11, 2015.
Canadian First Office Action corresponding to CA 2,686,105 dated Sep. 17, 2015.
Japanese Office Action corresponding to JP 2012-040188 dated Oct. 21, 2015.
European Communication corresponding to EP 13 17 6895.4 dated Nov. 5, 2015.
Chinese First Office Action corresponding to CN 201210544552 dated Nov. 23, 2015.
Chinese First Office Action corresponding to CN 201210545228 dated Nov. 30, 2015.
Extended European Search Report corresponding to EP 15 18 0491.1 dated Dec. 9, 2015.
Extended European Search Report corresponding to EP 15 18 3819.0 dated Dec. 11, 2015.
Canadian Office Action corresponding to CA 2,697,819 dated Jan. 6, 2016.
Canadian Office Action corresponding to CA 2,696,419 dated Jan. 14, 2016.
European Office Action corresponding to EP 12 19 8776.2 dated Jan. 19, 2016.
Extended European Search Report corresponding to EP 15 17 4146.9 dated Jan. 20, 2016.
Chinese First Office Action corresponding to CN 201310353628.5 dated Jan. 25, 2016.
Extended European Search Report corresponding to EP 12 19 6912.5 dated Feb. 1, 2016.
Japanese Office Action corresponding to JP 2012-098903 dated Feb. 22, 2016.
Extended European Search Report corresponding to EP 12 19 8753.1 dated Feb. 24, 2016.
Chinese First Office Action corresponding to CN 201410449019.4 dated Mar. 30, 2016.
Extended European Search Report corresponding to EP 16 15 0232.3 dated Apr. 12, 2016.
European Office Action corresponding to EP 11 18 3256.4 dated Apr. 20, 2016.
Australian Examination Report No. 1 corresponding to AU 2012244169 dated May 10, 2016.
European Office Action corresponding to EP 10 25 0715.9 dated May 12, 2016.
Chinese First Office Action corresponding to CN 201410778512.0 dated May 13, 2016.
Australian Examination Report No. 1 corresponding to AU 2012227358 dated May 16, 2016.
Japanese Office Action corresponding to JP 2012-040188 dated May 17, 2016.
Australian Examination Report No. 1 corresponding to AU 2012244380 dated May 20, 2016.
Australian Examination Report No. 1 corresponding to AU 2014227480 dated May 21, 2016.
Australian Examination Report No. 1 corresponding to AU 2012254977 dated May 30, 2016.
International Search Report and Written Opinion dated Sep. 30, 2022, issued in corresponding international application No. PCT/IB2022/055592, 12 pages.
European Office Action corresponding to EP 14 17 2681.0 dated May 13, 2016.
Extended European Search Report corresponding to EP 16 15 3647.9 dated Jun. 3, 2016.
Chinese Office Action corresponding to CN 201210545228 dated Jun. 29, 2016.
Japanese Office Action corresponding to JP 2012-250058 dated Jun. 29, 2016.
European Office Action corresponding to EP 14 15 7997.9 dated Jun. 29, 2016.
Canadian Office Action corresponding to CA 2,712,617 dated Jun. 30, 2016.
Chinese First Office Action corresponding to CN 2013103036903 dated Jun. 30, 2016.
Australian Patent Examination Report No. 1 corresponding to AU 2012250278 dated Jul. 10, 2016.
Australian Patent Examination Report No. 1 corresponding to AU 2012244382 dated Jul. 10, 2016.
Japanese Office Action corresponding to 2012-255242 dated Jul. 26, 2016.
Japanese Office Action corresponding to JP 2012-268668 dated Jul. 27, 2016.
European Office Action corresponding to EP 14 15 2060.1 dated Aug. 4, 2016.
European Office Action corresponding to EP 12 16 5609.4 dated Aug. 5, 2016.
European Office Action corresponding to EP 15 15 2392.5 dated Aug. 8, 2016.
Japanese Office Action corresponding to JP 2013-003624 dated Aug. 25, 2016.
Australian Patent Examination Report No. 1 corresponding to AU 2012261752 dated Sep. 6, 2016.
Japanese Office Action corresponding to JP 2014-252703 dated Sep. 26, 2016.
European Office Action corresponding to EP 12 19 8776.2 dated Sep. 12, 2016.
Japanese Office Action corresponding to JP 2013-000321 dated Sep. 13, 2016.
Chinese Second Office Action corresponding to CN 201310353628.5 dated Sep. 26, 2016.
European Office Action corresponding to EP 12 15 2541.4 dated Sep. 27, 2016.
Australian Patent Examination Report No. 1 corresponding to AU 2012268923 dated Sep. 28, 2016.
Chinese First Office Action corresponding to CN 2013107068710 dated Dec. 16, 2016.
Chinese First Office Action corresponding to CN 201310646606.8 dated Dec. 23, 2016.
Japanese Office Action corresponding to JP 2013-000321 dated Jan. 4, 2017.
Extended European Search Report corresponding to EP 16 16 6367.9 dated Jan. 16, 2017.
Australian Examination Report No. 1 corresponding to AU 2013206777 dated Feb. 1, 2017.
Chinese Second Office Action corresponding to CN 2013103036903 dated Feb. 23, 2017.
Japanese Office Action corresponding to JP 2013-175379 dated Mar. 1, 2017.
Chinese First Office Action corresponding to CN 201410028462.4 dated Mar. 2, 2017.
Chinese First Office Action corresponding to CN 201410084070 dated Mar. 13, 2017.
Extended European Search Report corresponding to EP 16 19 6549.6 dated Mar. 17, 2017.
Japanese Office Action corresponding to JP 2013-147701 dated Mar. 21, 2017.
Australian Examination Report No. 1 corresponding to AU 2013206804 dated Mar. 21, 2017.
Australian Examination Report No. 1 corresponding to AU 2013211499 dated May 4, 2017.
Australian Examination Report No. 1 corresponding to AU 2014201008 dated May 23, 2017.
European Office Action corresponding to EP 15 17 4146.9 dated May 15, 2017.
Japanese Office Action corresponding to JP 2013-154561 dated May 23, 2017.
European Office Action corresponding to EP 12 19 4784.0 dated May 29, 2017.
Japanese Office Action corresponding to JP 2013-169083 dated May 31, 2017.
Australian Examination Report No. 1 corresponding to AU 2013213767 dated Jun. 29, 2017.
Australian Examination Report No. 2 corresponding to AU 2012261752 dated Jul. 7, 2017.
Australian Examination Report No. 1 corresponding to AU 2013266989 dated Jul. 10, 2017.
Extended European Search Report corresponding to EP 14 15 3609.4 dated Jul. 14, 2017.
Australian Examination Report No. 1 corresponding to AU 2013234418 dated Jul. 14, 2017.
Extended European Search Report corresponding to EP 14 15 3610.2 dated Jul. 17, 2017.
Australian Examination Report No. 1 corresponding to AU 2014200109 dated Jul. 20, 2017.
Australian Examination Report No. 1 corresponding to AU 2014200074 dated Jul. 20, 2017.
Japanese Office Action corresponding to JP 2013-250857 dated Aug. 17, 2017.
Japanese Office Action corresponding to JP 2013-229471 dated Aug. 17, 2017.
Australian Examination Report No. 1 corresponding to AU 2014200793 dated Sep. 2, 2017.
Extended European Search Report corresponding to EP 17 17 8528.0 dated Oct. 13, 2017.
Australian Examination Report No. 1 corresponding to AU 2013234420 dated Oct. 24, 2017.
Japanese Office Action corresponding to JP 2013-175379 dated Oct. 20, 2017.
Japanese Office Action corresponding to JP 2013-147701 dated Oct. 27, 2017.
Extended European Search Report corresponding to EP 17 17 5656.2 dated Nov. 7, 2017.
Japanese Office Action corresponding to JP 2014-009738 dated Nov. 14, 2017.
European Office Action corresponding to EP 13 17 3986.4 dated Nov. 29, 2017.
Japanese Office Action corresponding to JP 2017-075975 dated Dec. 4, 2017.
European Office Action corresponding to EP 13 19 7958.5 dated Dec. 11, 2017.
Chinese First Office Action corresponding to Patent Application CN 201410588811.8 dated Dec. 5, 2017.
European Office Action corresponding to Patent Application EP 16 16 6367.9 dated Dec. 11, 2017.
Chinese First Office Action corresponding to Patent Application CN 201610279682.3 dated Jan. 10, 2018.
Japanese Office Action corresponding to Patent Application JP 2013-154561 dated Jan. 15, 2018.
Australian Examination Report No. 1 corresponding to Patent Application AU 2017225037 dated Jan. 23, 2018.
Japanese Office Action corresponding to Patent Application JP 2013-229471 dated May 1, 2018.
Canadian Office Action corresponding to Patent Application CA 2,790,743 dated May 14, 2018.
European Office Action corresponding to Patent Application EP 14 15 7195.0 dated Jun. 12, 2018.
Extended European Search Report corresponding to Patent Application EP 12196912.5 dated Feb. 1, 2016.
Chinese Second Office Action corresponding to Patent Application CN 201610279682.3 dated Aug. 8, 2018.
Chinese Second Office Action corresponding to Patent Application CN 201410588811.8 dated Aug. 27, 2018.
Extended European Search Report corresponding to Patent Application EP 18160809.2 dated Sep. 18, 2018.
Extended European Search Report corresponding to Patent Application EP 18192317.8 dated Dec. 20, 2018.
Extended European Search Report corresponding to Patent Application EP 18190154.7 dated Feb. 4, 2019.
European Search Report corresponding to EP 06 00 4598, completed Jun. 22, 2006; (2 pp).
European Search Report corresponding to EP 06 01 6962.0, completed Jan. 3, 2007 and dated Jan. 11, 2007; (10 pp).
International Search Report corresponding to International Application No. PCT/US2005/036740, completed Feb. 20, 2007 and dated Mar. 23, 2007; (8 pp).
International Search Report corresponding to International Application No. PCT/US2007/022713, completed Apr. 21, 2008 and dated May 15, 2008; (1 p).
International Search Report corresponding to International Application No. PCT/US2008/002981, completed Jun. 9, 2008 and dated Jun. 26, 2008; (2 pp).
European Search Report corresponding to EP 08 25 1779, completed Jul. 14, 2008 and dated Jul. 23, 2008; (5 pp).
European Search Report corresponding to EP 08 25 1989.3, completed Mar. 11, 2010 and dated Mar. 24, 2010; (6 pp).
European Search Report corresponding to EP 10 25 0639.1, completed Jun. 17, 2010 and dated Jun. 28, 2010; (7 pp).
European Search Report corresponding to EP 10 25 0715.9, completed Jun. 30, 2010 and dated Jul. 20, 2010; (3 pp).
European Search Report corresponding to EP 05 80 4382.9, completed Oct. 5, 2010 and dated Oct. 12, 2010; (3 pp).
European Search Report corresponding to EP 09 25 2897.5, completed Feb. 7, 2011 and dated Feb. 15, 2011; (3 pp).
European Search Report corresponding to EP 10 25 0642.5, completed Mar. 25, 2011 and dated Apr. 4, 2011; (4 pp).
European Search Report corresponding to EP 12 15 2229.6, completed Feb. 23, 2012 and dated Mar. 1, 2012; (4 pp).
European Search Report corresponding to EP 12 15 0511.9, completed Apr. 16, 2012 and dated Apr. 24, 2012; (7 pp).
European Search Report corresponding to EP 12 15 2541.4, completed Apr. 23, 2012 and dated May 3, 2012; (10 pp).
European Search Report corresponding to EP 12 16 5609.4, completed Jul. 5, 2012 and dated Jul. 13, 2012; (8 pp).
European Search Report corresponding to EP 12 15 8861.0, completed Jul. 17, 2012 and dated Jul. 24, 2012; (9 pp).
European Search Report corresponding to EP 12 16 5878.5, completed Jul. 24, 2012 and dated Aug. 6, 2012; (8 pp).
Extended European Search Report corresponding to EP 12 19 1035.0, completed Jan. 11, 2013 and dated Jan. 18, 2013; (7 pp).
Extended European Search Report corresponding to EP 12 18 6175.1, completed Jan. 15, 2013 and dated Jan. 23, 2013; (7 pp).
Extended European Search Report corresponding to EP 12 19 1114.3, completed Jan. 23, 2013 and dated Jan. 31, 2013; (10 pp).
Extended European Search Report corresponding to EP 12 19 2224.9, completed Mar. 14, 2013 and dated Mar. 26, 2013; (8 pp).
Extended European Search Report corresponding to EP 12 19 6904.2, completed Mar. 28, 2013 and dated Jul. 26, 2013; (8 pp).
Extended European Search Report corresponding to EP 12 19 6911.7, completed Apr. 18, 2013 and dated Apr. 24, 2013; (8 pp).
Extended European Search Report corresponding to EP 07 00 5842.5, completed May 13, 2013 and dated May 29, 2013; (7 pp).
Extended European Search Report corresponding to EP 12 19 8776.2, completed May 16, 2013 and dated May 27, 2013; (8 pp).
Extended European Search Report corresponding to EP 12 19 8749.9, completed May 21, 2013 and dated May 31, 2013; (8 pp).
Extended European Search Report corresponding to EP 13 15 6297.7, completed Jun. 4, 2013 and dated Jun. 13, 2013; (7 pp).
Extended European Search Report corresponding to EP 13 17 3985.6, completed Aug. 19, 2013 and dated Aug. 28, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 17 3986.4, completed Aug. 20, 2013 and dated Aug. 29, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 17 7437.4, completed Sep. 11, 2013 and dated Sep. 19, 2013; 6 pages.
Extended European Search Report corresponding to EP 13 17 7441.6, completed Sep. 11, 2013 and dated Sep. 19, 2013; (6 pp).
Extended European Search Report corresponding to EP 07 86 1534.1, completed Sep. 20, 2013 and dated Sep. 30, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 18 3876.5, completed Oct. 14, 2013 and dated Oct. 24, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 17 1856.1, completed Oct. 29, 2013 and dated Nov. 7, 2013; (8 pp).
Extended European Search Report corresponding to EP 13 18 0373.6, completed Oct. 31, 2013 and dated Nov. 13, 2013; (7 pp).
Extended European Search Report corresponding to EP 13 18 0881.8, completed Nov. 5, 2013 and dated Nov. 14, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 17 6895.4, completed Nov. 29, 2013 and dated Dec. 12, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 18 2911.1, completed Dec. 2, 2013 and dated Dec. 16, 2013; (8 pp).
Extended European Search Report corresponding to EP 10 25 1795.0, completed Dec. 11, 2013 and dated Dec. 20, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 18 7911.6, completed Jan. 22, 2014 and dated Jan. 31, 2014; (8 pp).
Extended European Search Report corresponding to EP 13 19 2111.6, completed Feb. 13, 2014 and dated Feb. 27, 2014; (10 pp).
Extended European Search Report corresponding to EP 13 19 5919.9, completed Feb. 10, 2014 and dated Mar. 3, 2014; (7 pp).
Extended European Search Report corresponding to EP 08 72 6500.5, completed Feb. 20, 2014 and dated Mar. 3, 2014; (7 pp).
Extended European Search Report corresponding to EP 13 19 5019.8, completed Mar. 14, 2014 and dated Mar. 24, 2014; (7 pp).
Extended European Search Report corresponding to EP 13 19 6816.6, completed Mar. 28, 2014 and dated Apr. 9, 2014; (9 pp).
Extended European Search Report corresponding to EP 13 19 7958.5, completed Apr. 4, 2014 and dated Apr. 15, 2014; (8 pp).
Extended European Search Report corresponding to EP 13 19 4995.0, completed Jun. 5, 2014 and dated Jun. 16, 2014; (5 pp).
Extended European Search Report corresponding to EP 14 15 7195.0, completed Jun. 5, 2014 and dated Jun. 18, 2014; (9 pp).
Extended European Search Report corresponding to EP 14 15 6342.9, completed Jul. 22, 2014 and dated Jul. 29, 2014; (8 pp).
Related Publications (1)
Number Date Country
20220409206 A1 Dec 2022 US